Automate Your Wheel Strategy on KVUE
With Tiblio's Option Bot, you can configure your own wheel strategy including KVUE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KVUE
- Rev/Share 7.8238
- Book/Share 5.5443
- PB 2.9291
- Debt/Equity 0.8438
- CurrentRatio 0.9799
- ROIC 0.0767
- MktCap 31123555819.0
- FreeCF/Share 0.8545
- PFCF 18.9894
- PE 21.7364
- Debt/Assets 0.3293
- DivYield 0.0508
- ROE 0.1395
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | KVUE | Canaccord Genuity | Buy | Hold | -- | $15 | Oct. 29, 2025 |
| Upgrade | KVUE | Rothschild & Co Redburn | Neutral | Buy | -- | $22 | Sept. 26, 2025 |
| Initiation | KVUE | Redburn Atlantic | -- | Neutral | -- | $23.5 | April 10, 2025 |
| Initiation | KVUE | Evercore ISI | -- | In-line | -- | $25 | March 24, 2025 |
| Upgrade | KVUE | Piper Sandler | Neutral | Overweight | $21 | $26 | Jan. 6, 2025 |
| Downgrade | KVUE | Deutsche Bank | Buy | Hold | $25 | $24 | Dec. 12, 2024 |
| Initiation | KVUE | Jefferies | -- | Buy | -- | $27 | Sept. 24, 2024 |
| Downgrade | KVUE | RBC Capital Mkts | Outperform | Sector Perform | -- | $24 | Sept. 24, 2024 |
News
Buy 3 Ideal Dividend Kings Of 24 'Safer' In November's 56
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Positive
The article reviews the November 2025 Dividend Kings, highlighting 56 stocks with long dividend growth records and recent changes to the list. Six Dividend Kings - MO, UVV, HRL, KVUE, CDUAF, UBSI - are currently fairly priced, with annual dividends from $1,000 invested meeting or exceeding share prices. Analyst forecasts suggest top-yielding Kings could deliver net gains of 18.55% to 101.43% by November 2026, with Stepan, H2O America, and National Fuel Gas among the top projections.
Read More
Why Tylenol maker stock is popping despite Trump's autism warning
Published: November 03, 2025 by: Finbold
Sentiment: Positive
Kenvue (NYSE: KVUE) shares surged Monday, climbing by double digits as investors cheered news that consumer goods giant Kimberly-Clark (NASDAQ: KMB) plans to acquire the Tylenol maker
Read More
KVUE Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Kenvue to Kimberly-Clark
Published: November 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
MONSEY, N.Y., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) to Kimberly-Clark pursuant to which Kenvue shareholders will receive $3.50 per share in cash as well as 0.14625 Kimberly-Clark shares for each Kenvue share held at closing, for an implied sale price of $21.01 per share, based on the closing price of Kimberly-Clark shares as of October 31, 2025.
Read More
Kimberly-Clark to buy Tylenol maker Kenvue in massive consumer merger
Published: November 03, 2025 by: The Street
Sentiment: Positive
The deal would bring Huggies, Kleenex, Band-Aid, Neutrogena, and Tylenol under one roof, creating a consumer staples giant. Transcript: Caroline Woods: Big brands and big money - Kimberly-Clark is buying Kenvue in a nearly $50 billion cash and stock deal.
Read More
Kimberly-Clark Is Buying Tylenol Maker Kenvue for Nearly $49B. Here's What You Need to Know
Published: November 03, 2025 by: Investopedia
Sentiment: Positive
Kenvue (KVUE) shares skyrocketed in early trading Monday after Kleenex and Cottonelle maker Kimberly-Clark (KMB) said it's buying the Tylenol maker in a $48.7 billion deal.
Read More
Kimberly-Clark to acquire Tylenol-maker Kenvue in $48.7B deal
Published: November 03, 2025 by: Proactive Investors
Sentiment: Positive
Kimberly-Clark Corp (NYSE:KMB, ETR:KMY) announced it will acquire Kenvue (NYSE:KVUE), the maker of Tylenol and other consumer health products, in a cash and stock transaction valued at approximately $48.7 billion. Under the agreement, Kenvue shareholders will receive $3.50 per share in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share, totaling $21.01 per share based on Kimberly-Clark's recent stock price.
Read More
Kimberly-Clark Buying Tylenol Maker Kenvue in $40 Billion Deal
Published: November 03, 2025 by: Bloomberg Markets and Finance
Sentiment: Positive
Kimberly-Clark agreed to buy Kenvue in a deal worth roughly $40 billion in a combination that could create a company with $32 billion in revenue and allow it to surpass Unilever to become the second-biggest seller of health and wellness products after Procter & Gamble. Eric Pfanner reports on Bloomberg Television.
Read More
Tylenol Maker Eyes Best Day Ever on Kimberly-Clark Deal
Published: November 03, 2025 by: Schaeffers Research
Sentiment: Positive
Tylenol maker and former Johnson & Johnson (JNJ) spinoff Kenvue Inc (NYSE:KVUE) is 16.7% higher to trade at $16.74, after Kimberly-Clark Corp (NASDAQ:KMB) agreed to purchase the pharma name for $48.70 billion in cash and stock.
Read More
Shareholder Alert: The Ademi Firm investigates whether Kenvue Inc. is obtaining a Fair Price for its Public Shareholders
Published: November 03, 2025 by: PRNewsWire
Sentiment: Neutral
MILWAUKEE , Nov. 3, 2025 /PRNewswire/ -- The Ademi Firm is investigating Kenvue (NYSE: KVUE) for possible breaches of fiduciary duty and other violations of law in its transaction with Kimberly-Clark. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
Read More
Kimberly-Clark buys Tylenol maker Kenvue in a cash and stock deal for $48.7 billion
Published: November 03, 2025 by: New York Post
Sentiment: Positive
Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.
Read More
Activist Investors in Kenvue Faced Big Losses. Kimberly-Clark Saved the Day.
Published: November 03, 2025 by: WSJ
Sentiment: Neutral
D.E. Shaw, one of the Tylenol-maker's largest shareholders, stood to lose over $200 million but is now expected to break even on its bet.
Read More
Another Big Earnings Week Ahead, KVUE Soars on KMB $48.7B Deal
Published: November 03, 2025 by: Schwab Network
Sentiment: Positive
While all the Mag 7 but Nvidia (NVDA) reported their quarterly earnings, 135 SPX companies and 25 NDX companies are on the docket this week. Kevin Hincks points to Palantir's (PLTR) report after Monday's close opening the earnings flood gate.
Read More
Earnings Preview: Kenvue (KVUE) Q3 Earnings Expected to Decline
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Negative
Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Kenvue: Temporary Headwinds Don't Derail Its Consumer Health Dominance And 5.5% Dividend Yield
Published: October 29, 2025 by: Seeking Alpha
Sentiment: Positive
Kenvue offers a defensive, dividend-rich investment opportunity after a 34% stock decline, trading at a 10% discount to peers. KVUE's 5.5% dividend yield and strong operating margins make it attractive for long-term, income-focused investors seeking diversification in consumer staples. Despite recent top- and bottom-line weakness, current headwinds may be priced in, with a potential rebound as consumer spending improves and interest rates fall.
Read More
US health chief says not enough data to show Tylenol causes autism, but still advises caution
Published: October 29, 2025 by: Reuters
Sentiment: Neutral
U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday said there is not enough evidence to show that Kenvue's pain medicine Tylenol definitively causes autism, but said that it should still be used cautiously in consultation with a physician.
Read More
Kenvue Declares Quarterly Cash Dividend
Published: October 29, 2025 by: Business Wire
Sentiment: Neutral
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on November 26, 2025, to shareholders of record as of the close of business on November 12, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, John.
Read More
Embattled Tylenol Maker Kenvue Hires New Marketing Chief
Published: October 28, 2025 by: WSJ
Sentiment: Negative
The company plans to name snack food executive Jon Halvorson as it faces a crisis over concerns of links between Tylenol and autism.
Read More
Texas sues J&J and Kenvue, claiming they hid Tylenol's autism risks
Published: October 28, 2025 by: Reuters
Sentiment: Negative
The makers of Tylenol, Johnson & Johnson and Kenvue , were sued on Tuesday by Texas Attorney General Ken Paxton, who accused them of knowingly hiding the drug's links to autism and attention deficit hyperactivity disorder.
Read More
Time To Buy The Dip In Kenvue Stock?
Published: October 27, 2025 by: Forbes
Sentiment: Negative
Kenvue (NYSE:KVUE), the consumer healthcare spin-off from Johnson & Johnson, has experienced a significant decline in its stock price in recent months. The shares are currently priced around $15, which is more than 65% lower than their highs in 2023, as investors contend with legal uncertainties, management changes, and slowing sales growth.
Read More
Top Stock Movers Now: Oracle, Newmont, Kenvue, American Express, and More
Published: October 17, 2025 by: Investopedia
Sentiment: Positive
Major U.S. equities indexes climbed at midday Friday as regional bank stocks rebounded from yesterday's losses after a flurry of corporate earnings reports. The Dow, S&P 500, and Nasdaq were all higher.
Read More
Albert Invent Partners with Kenvue to Build the Future of Consumer Health Products With the Help of AI
Published: October 14, 2025 by: Business Wire
Sentiment: Neutral
SUMMIT, N.J. & OAKLAND, Calif.--(BUSINESS WIRE)--Frontier AI company Albert Invent today announced a strategic partnership with Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Zyrtec®, Neutrogena®, and Listerine®, to accelerate end-to-end R&D efforts across the company's global portfolio of brands. The partnership enables Kenvue to streamline, digitalize, and accelerate the end-to-end product lifecycle by leveraging Albert Invent's foundational AI models. The companies bega.
Read More
These Were the 5 Worst-Performing Stocks in the S&P 500 in September 2025 -- and One's Decline Can Be Tied to President Trump
Published: October 08, 2025 by: The Motley Fool
Sentiment: Negative
It's fun to follow stocks that soared recently, and it can be sobering to see which ones have plunged -- especially if you're a shareholder. So here's a look at the worst-performing stocks in the S&P 500 index of 500 of America's biggest companies -- in September.
Read More
Does Tylenol cause autism? Researchers can use ‘natural experiments' to study the link, write Drs.
Published: October 03, 2025 by: WSJ
Sentiment: Neutral
In the absence of randomized trials on the effects of acetaminophen, researchers need to use ‘natural experiments' to develop better guidance for patients.
Read More
Kenvue: This Too Shall Pass
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Positive
Kenvue shares have dropped 17% following reports linking Tylenol to autism, creating a potential long-term buying opportunity. The market reaction appears to be an overreaction, as Tylenol accounts for roughly $1 billion in sales and a fraction of Kenvue's total revenue. The current valuation implies an unrealistic 40%+ decline in Tylenol sales, which seems excessive given the actual business impact.
Read More
Trump links autism to Tylenol ingredient use during pregnancy — here's what to know
Published: September 24, 2025 by: CNBC Television
Sentiment: Neutral
The Trump administration on Monday drew an unproven link between autism and pregnant women's use of acetaminophen, the active ingredient in one of the world's most common over-the-counter pain relievers, Kenvue's Tylenol. CNBC's Angelica Peebles explains.
Read More
Kenvue Stock Recoups Losses After Trump Links Tylenol to Autism
Published: September 23, 2025 by: Investopedia
Sentiment: Neutral
Kenvue stock is rebounding. It may be a largely a case of things-could've-been- worse.
Read More
Trading meme stocks, gold, and crypto, Kenvue's stock rebounds
Published: September 23, 2025 by: Yahoo Finance
Sentiment: Positive
Opening Bid anchor Brian Sozzi breaks down the latest market news for September 23, 2025. Our panel looks at the latest moves in meme stocks Opendoor and Better Homes, weakness in the crypto market, and gold's continued climb to new highs.
Read More
Pharmaceutical Stock Bounces Off Record Lows
Published: September 23, 2025 by: Schaeffers Research
Sentiment: Positive
Kenvue Inc (NYSE:KVUE) stock is up 3.9% to trade at $17.62 at last check, erasing some of yesterday's losses that followed the Trump administration connection between the use of acetaminophen -- the active ingredient of the company's Tylenol pain drug -- in pregnancy and autism.
Read More
Tylenol: Kenvue's Sobering Reality
Published: September 23, 2025 by: Seeking Alpha
Sentiment: Negative
I'm initiating Kenvue Inc. with a Buy after a sharp selloff following President Donald Trump's remarks on Monday linking Tylenol with autism. KVUE's profitability, with gross margins above 58% and EBITDA margins over 23%, provides resilience against legal and headline risks. Despite Self Care sales weakness and ongoing litigation concerns, Tylenol continues to gain market share and new product launches are underway.
Read More
Shares of Kenvue rebound today after Trump admin ties use of acetaminophen to autism
Published: September 23, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on the Trump administration's announcement linking acetaminophen taken during pregnancy to autism.
Read More
About Kenvue Inc. (KVUE)
- IPO Date 2023-05-04
- Website https://www.kenvue.com
- Industry Household & Personal Products
- CEO Kirk L. Perry
- Employees 22000